^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

zorifertinib (AZD3759)

i
Other names: AZD3759, AZD-3759, AZD 3759
Company:
Alpha Biopharma, AstraZeneca
Drug class:
EGFR inhibitor
Related drugs:
1m
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial. (PubMed, Med)
Zorifertinib significantly improved systemic and intracranial PFS versus first-generation EGFR-TKIs; adverse events were manageable. Sequential use of zorifertinib and third-generation EGFR-TKIs showed the potential to prolong patients' survival. The results favor zorifertinib as a novel, well-validated first-line option for CNS-metastatic patients with EGFR-mutant NSCLC.
P3 data • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R
|
erlotinib • gefitinib • zorifertinib (AZD3759)
5ms
Long-term survival of a patient with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) and untreated multiple brain metastases treated with zorifertinib: A case report. (PubMed, Thorac Cancer)
This is the first report of a patient with EGFR-mutant (exon 21 L858R) NSCLC and symptomatic untreated multiple BM who achieved a long overall survival (OS) of more than 65 months after sequential treatment with zorifertinib and a third-generation EGFR-TKI. This new treatment paradigm offers a new treatment option and deserves further clinical exploration to prolong OS of patients with EGFR-mutant NSCLC and untreated multiple BM.
Clinical • Observational data • Retrospective data • Review • Clinical Trial,Phase III • Journal
|
EGFR (Epidermal growth factor receptor)
|
zorifertinib (AZD3759)
9ms
A Six-gene Prognostic Model Based on Neutrophil Extracellular Traps (NETs)-related Gene Signature for Lung Adenocarcinoma. (PubMed, Comb Chem High Throughput Screen)
Altogether, this study has identified a novel NET-score signature based on six novel NET-related genes to predict the prognosis of LUAD and ABCC2 and has also explored a new method for personalized chemo-/immuno-therapy of LUAD.
Journal • Gene Signature • IO biomarker
|
ABCC2 (ATP Binding Cassette Subfamily C Member 2) • UPK1B (Uroplakin 1B)
|
dasatinib • lapatinib • zorifertinib (AZD3759)
10ms
Molecular prognostic of nine parthanatos death-related genes in glioma, particularly in COL8A1 identification. (PubMed, J Neurochem)
Low-score glioma patients were sensitive to AZD3759_1915, AZD5582_1617, AZD8186_1918, Dasatinib_1079, and Temozolomide_1375, while high-score patients were less sensitive to these drugs. Silencing COL8A1 inhibited the malignant characterization. Temozolomide and AZD3759 inhibited COL8A1 expression and cell viability and promoted apoptosis and parthanatos gene expression, which is a target to improve glioma.
Journal
|
CD58 (CD58 Molecule) • COL8A1 (Collagen Type VIII Alpha 1 Chain) • FABP5 (Fatty Acid Binding Protein 5) • TNFRSF11B (Tumor necrosis factor receptor superfamily member 11B)
|
dasatinib • temozolomide • AZD8186 • zorifertinib (AZD3759)
1year
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial. (PubMed, EClinicalMedicine)
The median overall survival was 33.7 months, and 34.1 months and 25.3 months in patient treated with or without osimertinib in a later-line setting, respectively. Sequential use of AZD3759 and third-generation EGFR-TKIs represents a new option. Chinese Thoracic Oncology Group (CTONG).
P2 data • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
Tagrisso (osimertinib) • zorifertinib (AZD3759)
over1year
Identification of the novel markers of PPAR signalling affecting immune microenvironment and immunotherapy response of lung adenocarcinoma patients. (PubMed, J Cell Mol Med)
Intriguingly, high-risk patients exhibited a potential heightened sensitivity to immunotherapy and certain drugs, including Gefitinib, Afatinib, Erlotinib, IAP_5620, Sapitinib, LCL161, Lapatinib and AZD3759. The prognosis model based on eight PPAR-related genes has satisfactory prognosis prediction efficiency. Meanwhile, our results can provide direction for future studies in the relevant aspects.
Journal • IO biomarker
|
ACSL3 (Acyl-CoA Synthetase Long Chain Family Member 3) • FABP1 (Fatty Acid Binding Protein 1)
|
erlotinib • Gilotrif (afatinib) • gefitinib • lapatinib • zorifertinib (AZD3759) • LCL161 • sapitinib (AZD8931)
over1year
Developing CuS for Predicting Aggressiveness and Prognosis in Lung Adenocarcinoma. (PubMed, Genes (Basel))
Furthermore, we predicted six potential drugs targeting high-CuS patients, including AZD3759, which is a targeted drug for LUAD. In conclusion, cuproptosis is involved in LUAD aggressiveness, and CuS can accurately predict the prognosis of patients. These findings provide a basis for precise treatment of patients with high CuS in LUAD.
Journal
|
zorifertinib (AZD3759)
over1year
An individual patient-level meta-analysis of non–small-cell lung cancer leptomeningeal metastases treated with epidermal growth factor receptor inhibitors. (ASCO 2023)
EGFR-TTs evaluated were erlotinib, gefitinib, icotinib, afatinib, dacomitinib, osimertinib, zorifertinib, and furmonertinib. In the largest cohort of NSCLC LM treated with EGFR TT compiled to date, osimertinib is associated with marginally improved outcomes compared to other EGFR TTs. ECOG performance status is an independent predictor of prognosis in these patients. These results highlight the need for prospective studies for this difficult to treat patient population.
Retrospective data
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • Conmana (icotinib) • Vizimpro (dacomitinib) • Ivesa (firmonertinib) • zorifertinib (AZD3759)
over1year
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. (ASCO 2023)
First-line AZD3759 demonstrated superior systemic and IC antitumor efficacy compared with first generation EGFR TKIs in pts with EGFRm+ NSCLC and CNS metastasis. Adverse events were as expected and manageable. IC antitumor activity.
Clinical • P3 data
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
erlotinib • gefitinib • zorifertinib (AZD3759)
over1year
Efficacy and safety of AZD3759 in previously untreated EGFR-mutant non-small-cell lung cancer with central nervous system metastases in a multi-center, phase 2 umbrella trial (CTONG1702) (ELCC 2023)
We suggested 200 mg BID was a better dose with superior response and lower toxicity. EGFR T790M was the most common resistant mutation, and these patients still have the opportunity to receive osimertinib after progression of AZD3759.
Clinical • P2 data
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
Tagrisso (osimertinib) • zorifertinib (AZD3759)
almost2years
Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 (clinicaltrials.gov)
P1/2, N=15, Completed, LYZZ Alpha Holding Ltd | Unknown status --> Completed
Trial completion
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
zorifertinib (AZD3759)
almost2years
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (clinicaltrials.gov)
P2/3, N=492, Completed, Alpha Biopharma (Jiangsu) Co., Ltd. | Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Jul 2022 | Trial primary completion date: Oct 2022 --> Jul 2022
Trial completion • Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
erlotinib • gefitinib • zorifertinib (AZD3759)
over2years
Estimation of zorifertinib metabolic stability in human liver microsomes using LC-MS/MS. (PubMed, J Pharm Biomed Anal)
ZFB and encorafenib (ENF) (internal standard; IS) were separated through the use of an isocratic mobile phase system with a C stationary phase column. ZFB exhibited a moderate extraction ratio that revealed good bioavailability. Literature review demonstrated that the developed analytical method is the first developed LC-MS/MS method for determining ZFB metabolic stability.
Journal
|
EGFR (Epidermal growth factor receptor)
|
Braftovi (encorafenib) • zorifertinib (AZD3759)
3years
AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1. (PubMed, Bioengineered)
AZD3759 is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) on the basis of gefitinib and has been proven to enter the central nervous system...The present study aimed to compare the effects of AZD3759 and osimertinib on RA efficacy in NSCLC and explore the potential mechanism of action of AZD3759...The effects of AZD3759 on RA efficacy in PC-9 cells and in a brain metastasis animal model were significantly abolished by the overexpression of JAK1. Collectively, our results suggested that AZD3759 promoted RA antitumor effects in NSCLC by synergistic blockade of EGFR and JAK1.
Journal
|
EGFR (Epidermal growth factor receptor) • JAK1 (Janus Kinase 1)
|
JAK1 overexpression
|
Tagrisso (osimertinib) • gefitinib • zorifertinib (AZD3759)
3years
AZD3759 inhibits glioma through the blockade of the epidermal growth factor receptor and Janus kinase pathways. (PubMed, Bioengineered)
The inhibitory effects of AZD3759 on the Janus kinase (JAK)/STAT pathway were observed in both glioma cells and tumor tissues, which were more significant than those of osimertinib. In conclusion, AZD3759 may inhibit the progression of glioma via a synergistic blockade of the EGFR and JAK/STAT signaling pathways.
Journal
|
EGFR (Epidermal growth factor receptor)
|
Tagrisso (osimertinib) • zorifertinib (AZD3759)
over3years
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (clinicaltrials.gov)
P2/3, N=492, Active, not recruiting, Alpha Biopharma (Jiangsu) Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2021 --> Nov 2022 | Trial primary completion date: Jun 2021 --> Aug 2022
Clinical • Enrollment closed • Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
erlotinib • gefitinib • zorifertinib (AZD3759)
over4years
Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 (clinicaltrials.gov)
P1/2, N=15, Active, not recruiting, LYZZ Alpha Holding Ltd | Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Nov 2020 | Trial primary completion date: Jun 2020 --> Nov 2020
Clinical • Enrollment closed • Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
zorifertinib (AZD3759)